Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.38 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.38 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484896 | 0.89 | CXCR2 (0.56) | CXCR2MRGPRX4LRRK2SENP5SENP2 | |
| SCHEMBL485218 | 0.89 | CXCR2 (0.56) | CXCR2MRGPRX4LRRK2SENP5SENP2 | |
| SCHEMBL3926067 | 0.86 | CXCR2 (0.56) | CXCR2SENP5SENP2SENP1P2RX7 | |
| SCHEMBL3930274 | 0.86 | CXCR2 (0.80) | CXCR2MRGPRX4LRRK2SENP5SENP2 | |
| SCHEMBL485166 | 0.81 | CXCR2 (0.69) | CXCR2MRGPRX4LRRK2SENP5SENP2 | |
| SCHEMBL485249 | 0.79 | CXCR2 (0.55) | CXCR2MRGPRX4ERAP1CXCR5 | |
| SCHEMBL485432 | 0.79 | CXCR2 (0.54) | CXCR2SENP5SENP2SENP1ERAP1 | |
| SCHEMBL485510 | 0.79 | CXCR2 (0.56) | CXCR2SENP5SENP2SENP1ERAP1 | |
| SCHEMBL27693267 | 0.79 | CXCR2 (0.43) | CXCR2MRGPRX4LRRK2SENP5SENP2 | |
| SCHEMBL5180433 | 0.78 | CXCR2 (0.49) | CXCR2MRGPRX4ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | claimed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | claimed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | claimed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | claimed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215827-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885MRGPRX4 27/4885LRRK2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.